Literature DB >> 22178078

Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.

Kelly E Glajch1, Sheila M Fleming, D James Surmeier, Pavel Osten.   

Abstract

Parkinson's disease (PD), the second most common neurodegenerative disorder, is characterized by marked impairments in motor function caused by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc). Animal models of PD have traditionally been based on toxins, such as 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), that selectively lesion dopaminergic neurons. Motor impairments from 6-OHDA lesions of SNc neurons are well characterized in rats, but much less work has been done in mice. In this study, we compare the effectiveness of a series of drug-free behavioral tests in assessing sensorimotor impairments in the unilateral 6-OHDA mouse model, including six tests used for the first time in this PD mouse model (the automated treadmill "DigiGait" test, the challenging beam test, the adhesive removal test, the pole test, the adjusting steps test, and the test of spontaneous activity) and two tests used previously in 6-OHDA-lesioned mice (the limb-use asymmetry "cylinder" test and the manual gait test). We demonstrate that the limb-use asymmetry, challenging beam, pole, adjusting steps, and spontaneous activity tests are all highly robust assays for detecting sensorimotor impairments in the 6-OHDA mouse model. We also discuss the use of the behavioral tests for specific experimental objectives, such as simple screening for well-lesioned mice in studies of PD cellular pathophysiology or comprehensive behavioral analysis in preclinical therapeutic testing using a battery of sensorimotor tests.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178078      PMCID: PMC3324279          DOI: 10.1016/j.bbr.2011.12.007

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  81 in total

1.  Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion.

Authors:  K Matsuura; H Kabuto; H Makino; N Ogawa
Journal:  J Neurosci Methods       Date:  1997-04-25       Impact factor: 2.390

2.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry.

Authors:  Alexxai V Kravitz; Benjamin S Freeze; Philip R L Parker; Kenneth Kay; Myo T Thwin; Karl Deisseroth; Anatol C Kreitzer
Journal:  Nature       Date:  2010-07-07       Impact factor: 49.962

3.  Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats.

Authors:  T Schallert; I Q Whishaw; V D Ramirez; P Teitelbaum
Journal:  Science       Date:  1978-03-31       Impact factor: 47.728

Review 4.  Behavioral outcome measures for the assessment of sensorimotor function in animal models of movement disorders.

Authors:  Sheila M Fleming
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

5.  Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.

Authors:  M Olsson; G Nikkhah; C Bentlage; A Björklund
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

6.  A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.

Authors:  M Lundblad; B Picconi; H Lindgren; M A Cenci
Journal:  Neurobiol Dis       Date:  2004-06       Impact factor: 5.996

7.  Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease.

Authors:  Stefano Taverna; Ema Ilijic; D James Surmeier
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

8.  Walking pattern analysis after unilateral 6-OHDA lesion and transplantation of foetal dopaminergic progenitor cells in rats.

Authors:  Alexander Klein; Johanna Wessolleck; Anna Papazoglou; Gerlinde A Metz; Guido Nikkhah
Journal:  Behav Brain Res       Date:  2008-12-13       Impact factor: 3.332

9.  Somatotopic organization of the primate Basal Ganglia.

Authors:  Atsushi Nambu
Journal:  Front Neuroanat       Date:  2011-04-20       Impact factor: 3.856

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more
  52 in total

1.  Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson's disease via mechanisms associated with increased protein kinase activity in the striatum.

Authors:  Neha Milind Chitre; Bo Jarrett Wood; Azizi Ray; Nader H Moniri; Kevin Sean Murnane
Journal:  Neuropharmacology       Date:  2020-01-27       Impact factor: 5.250

2.  Peptide-Based Scaffolds for the Culture and Transplantation of Human Dopaminergic Neurons.

Authors:  Nicola L Francis; Nanxia Zhao; Hannah R Calvelli; Astha Saini; Janace J Gifford; George C Wagner; Rick I Cohen; Zhiping P Pang; Prabhas V Moghe
Journal:  Tissue Eng Part A       Date:  2019-10-17       Impact factor: 3.845

3.  Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits.

Authors:  Aysegul O Gezer; Joseph Kochmanski; Sarah E VanOeveren; Allyson Cole-Strauss; Christopher J Kemp; Joseph R Patterson; Kathryn M Miller; Nathan C Kuhn; Danielle E Herman; Alyssa McIntire; Jack W Lipton; Kelvin C Luk; Sheila M Fleming; Caryl E Sortwell; Alison I Bernstein
Journal:  Neurobiol Dis       Date:  2020-05-15       Impact factor: 5.996

4.  Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.

Authors:  Zili Luo; Katelin E Ahlers-Dannen; Mackenzie M Spicer; Jianqi Yang; Stephanie Alberico; Hanna E Stevens; Nandakumar S Narayanan; Rory A Fisher
Journal:  JCI Insight       Date:  2019-05-23

5.  CIQ, a positive allosteric modulator of GluN2C/D-containing N-methyl-d-aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease.

Authors:  Mona Nouhi; Xiaoqun Zhang; Ning Yao; Karima Chergui
Journal:  CNS Neurosci Ther       Date:  2017-12-11       Impact factor: 5.243

6.  Tyrosine Hydroxylase Inhibition in Substantia Nigra Decreases Movement Frequency.

Authors:  Michael F Salvatore; Tamara R McInnis; Mark A Cantu; Deana M Apple; Brandon S Pruett
Journal:  Mol Neurobiol       Date:  2018-07-28       Impact factor: 5.590

7.  Frequency-Specific Optogenetic Deep Brain Stimulation of Subthalamic Nucleus Improves Parkinsonian Motor Behaviors.

Authors:  Chunxiu Yu; Isaac R Cassar; Jaydeep Sambangi; Warren M Grill
Journal:  J Neurosci       Date:  2020-04-20       Impact factor: 6.167

8.  Prenatal ethanol exposure disrupts intraneocortical circuitry, cortical gene expression, and behavior in a mouse model of FASD.

Authors:  Hani El Shawa; Charles W Abbott; Kelly J Huffman
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

9.  Npas1+ Pallidal Neurons Target Striatal Projection Neurons.

Authors:  Kelly E Glajch; Daniel A Kelver; Daniel J Hegeman; Qiaoling Cui; Harry S Xenias; Elizabeth C Augustine; Vivian M Hernández; Neha Verma; Tina Y Huang; Minmin Luo; Nicholas J Justice; C Savio Chan
Journal:  J Neurosci       Date:  2016-05-18       Impact factor: 6.167

10.  Behavioural effects of basal ganglia rho-kinase inhibition in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Salim Yalcin Inan; Burak Cem Soner; Ayse Saide Sahin
Journal:  Metab Brain Dis       Date:  2016-03-21       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.